1. Home
  2. LGI vs WHWK Comparison

LGI vs WHWK Comparison

Compare LGI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$18.06

Market Cap

233.6M

Sector

N/A

ML Signal

HOLD

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$4.33

Market Cap

233.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGI
WHWK
Founded
2004
2007
Country
United States
United States
Employees
N/A
23
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.6M
233.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LGI
WHWK
Price
$18.06
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.50
AVG Volume (30 Days)
32.3K
298.5K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
7.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.32
$1.57
52 Week High
$19.88
$5.50

Technical Indicators

Market Signals
Indicator
LGI
WHWK
Relative Strength Index (RSI) 55.05 54.58
Support Level $17.29 $3.80
Resistance Level $18.37 $5.35
Average True Range (ATR) 0.30 0.28
MACD -0.03 -0.01
Stochastic Oscillator 74.49 54.76

Price Performance

Historical Comparison
LGI
WHWK

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Share on Social Networks: